(Q44733793)

English

Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

0 references

author name string

A J M Brnabic

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

K Kelin

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

H Ascher-Svanum

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

W Montgomery

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Z Kadziola

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

J Karagianis

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

publication date

1 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

International Journal of Clinical Practice

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

945-953

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

The cost of relapse and the predictors of relapse in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Clinical guideline recommendations for antipsychotic long-acting injections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Depot antipsychotic drugs. Place in therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Awareness of illness in schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Antipsychotic polypharmacy in schizophrenia: benefits and risks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Content and quality of 2000 controlled trials in schizophrenia over 50 years

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Readers should systematically assess methods used to identify, measure and analyze confounding in observational cohort studies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02743.X

21 January 2018

Identifiers

10.1111/J.1742-1241.2011.02743.X

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44733793&oldid=2035575838"